

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 12th August, 2025

To, The Secretary (DCS/Compliance), Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance), Corporate Relationship Department, National Stock Exchange of India Limited , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

Sub: Continuous Disclosure of material events or information under sub-clause 7 of Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015 for Change in designation of Mr. Ketan Shah (DIN: 08818212) from Whole Time Director to Chairman and Managing Director of the Company

Reference: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Script Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") with reference to the amended Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 regarding continuous disclosure requirement for listed entities; we are enclosing disclosure as required under sub-clause-7 of Para A of Part A of Schedule III regarding change in designation of Mr. Ketan Shah (DIN: 08818212) as Chairman and Managing Director of the Company w.e.f. 12th August, 2025.

Disclosure & Brief Profile of Directors are enclosed with this letter.

Further, we will also submit this continuous disclosure in prescribed format in XBRL mode (Excel Template provided by Exchange) along with the submission in PDF mode with in prescribed time limit.

The above information will also be available on the website of the Company at www.biofilgroup.net.

The Meeting of the Board of Directors commenced at 04:00 P.M. and concluded at 05:50 P.M.

You are requested to please take on record the above said information for your reference and further needful.

Thanking You,

Yours Faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

APOORV JAIN
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO. A71739

CONTINUAL DISCLOSURE UNDER SUB-CLAUSE 7 OF PARA A OF PART A OF SCHEDULE III PURSUANT TO REGULATION 30 OF THE SEBI (LODR) REGULATION, 2015

(Change in designation of Mr. Ketan Shah (DIN: 08818212) from whole time director to Chairman and Managing Director of the Company)

I. Reason for Change viz., appointment, ~~re-appointment, resignation, removal, death or otherwise:~~

Change in designation of Mr. Ketan Shah from whole time director to Chairman and Managing Director of the Company

II. A) Date of Appointment ~~/re-appointment/cessation:-~~ w.e.f. 12th August, 2025

B) Term of Appointment~~/re-appointment:~~ - for a period of 3 (Three) years w.e.f. 12th August, 2025 to 11th August, 2028 subject to approval of shareholders at the ensuing Annual General Meeting.

III. Brief Profile:-

PARTICULARS	Change in designation from Whole Time Director to Chairman and Managing Director of the Company
Name	Mr. Ketan Shah
Fathers name	Late Mr. Ramesh Shah
Director Identification No.	08818212
Date of Birth	21 st July, 1961
Age	64 years
Education/ Qualification	B.Sc.
Experience	39 years experience in Pharmaceuticals Industry
No. of company/ies in which directorship held except appointee company.	1 (One)

IV. Disclosure of Relationship between Directors:-

Mr. Ketan Shah is a promoter of the Company and uncle of Mr. Meet Shah, Non Executive Non independent Director of the Company.

Further the Company would like to bring to your notice that SEBI Letter dated June 14, 2018 read with Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/24 dated June 20, 2018 issued by BSE and NSE respectively, requires Listed Companies to ensure that the person proposed to be appointed as "Director" shall not be debarred from holding the office by virtue of any SEBI Order or any other authority.

In compliance to the Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 issued by BSE and Circular No. NSE/CML/2018/24 dated June 20, 2018 issued by NSE, we confirm that Shri Ketan Shah (DIN: 08818212), has not been debarred from holding the office of Director by virtue of any SEBI order or any other authority.

Thanking You,

Yours Faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

**APOORV JAIN
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO. A71739**